Results 21 to 30 of about 568,486 (233)
Atypical Refractory Macular Edema: Are We Missing Something?
Journal of Ophthalmic & Vision Research, 2022 Purpose: To report a case of bilateral refractory macular edema in a diabetic macular edema in a diabetic with an underlying systemic illness. Case Report: A 65-year-old male presented with the symptom of blurred vision in both eyes for three months.
Chaitra Jayadev +2 more
doaj +1 more source
International Journal of Molecular Sciences, 2022 Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries.
Sławomir Liberski +2 more
semanticscholar +1 more source
SAGE Open Medicine, 2020 Objectives: Blindness is one of the most widespread final pathways of diabetic retinopathy and its associated diabetic macular edema. The general practitioners are the first to encounter these diabetic patients.
Sultan H Al-Rashidi +4 more
doaj +1 more source
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema
Cells, 2022 Diabetic macular edema (DME) is a major ocular complication of diabetes mellitus (DM), leading to significant visual impairment. DME’s pathogenesis is multifactorial.
M. Chauhan +4 more
semanticscholar +1 more source
Pakistan Armed Forces Medical Journal, 2021 Objective: To investigate the effect of unilateral intravitreal Bevacizumab on contralateral eye in bilateral diabetic macular edema. Study Design: Quasi-experimental study.
Aziz Jan Bashir +5 more
doaj +3 more sources
Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema
Pharmaceutics, 2022 Diabetic retinopathy (DR) is one of the leading causes of blindness worldwide. Multiple treatment options have been used over time to attempt to modify the natural progression of the disease in both proliferative diabetic retinopathy (PDR) and diabetic ...
J. Gonzalez-Cortes +8 more
semanticscholar +1 more source
Aflibercept-Monotherapy versus Bevacizumab-First for Diabetic Macular Edema
New England Journal of Medicine, 2022 Background: In eyes with diabetic macular edema (DME), the relative efficacy of administering aflibercept monotherapy versus bevacizumab first and then switching to aflibercept if the eye is not improving sufficiently (a form of step therapy) is unknown.
Chirag Jhaveri +15 more
semanticscholar +1 more source
Laser treatment in diabetic retinopathy [PDF]
, 2007 Diabetic retinopathy is a leading cause of visual impairment and blindness in developed countries due to macular edema and proliferative diabetic retinopathy (PDR). For both complications laser treatment may offer proven therapy: the Diabetic Retinopathy
Ulbig, Michael W. +3 more
core +1 more source
Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Current Diabetes Reports, 2021 Purpose of Review This review highlights indications and evidence on laser therapy in the management of diabetic retinopathy and diabetic macular edema.
Lesley A. Everett, Y. Paulus
semanticscholar +1 more source
Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema [PDF]
, 2010 Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated
Haritoglou, Christos +6 more
core +1 more source